Latest Cervarix Stories

By Brian Brady WHITEHALL EDITOR A massive immunisation programme against cervical cancer is to be extended All women aged up to 24 could be offered a vaccine against one of the most common causes of cervical cancer in an extension to a multimillion-pound immunisation programme. Experts from the Department of Health are considering the case for offering women the latest protection against the human papilloma virus (HPV) as part of a concerted assault on a cancer that affects 2,700 people...

ATLANTA - An expensive vaccine aimed at preventing cervical cancer makes sense for young teens when it comes to cost- effectiveness, but not for women in their 20s, a new report contends. The vaccine against the HPV virus was licensed in 2006 for use in girls and women ages 9 to 26. Health officials recommend it for girls at age 11 or 12, and some doctors offer it to women in their 20s in "catch-up" vaccination campaigns. The maker of the Gardasil vaccine, Merck & Co., also wants to...

By The Associated Press ATLANTA (AP) - An expensive vaccine aimed at preventing cervical cancer makes sense for young teens when it comes to cost- effectiveness, but not for women in their 20s, contends a new report.The vaccine against the HPV virus was licensed in 2006 for use in girls and women ages 9 to 26. Health officials recommend it for girls at age 11 or 12, and some doctors offer it to women in their 20s in "catch-up" vaccination campaigns.The maker of the Gardasil vaccine, Merck &...

A new report claims that costly cervical cancer vaccines are less-cost effective for women in their 20s than they are for young teens. Merck & Co's Gardasil vaccine protects young women against the HPV virus, and has been approved for use in those aged 9 to 26. Doctors recommend Gardasil to girls at age 11 or 12, and some doctors offer it to women in their 20s. Merck and Co. would like to be able to market it to women ages 27 to 45, but so far the U.S. Food and Drug Administration won't...

By Elisabeth Rosenthal In two years, cervical cancer has gone from obscure killer confined mostly to poor nations to the West's disease of the moment. Tens of millions of girls and young women in the United States and Europe have been vaccinated against a virus that can cause many types of the disease in the two years since two vaccines were given government approval in many countries and, often, recommended for universal use among females ages 11 to 26. One of the vaccines, Gardasil,...

By Liz Szabo A new economic analysis shows that the HPV vaccine, which protects against the viruses that cause most cervical cancers and genital warts, could be a good financial investment in public health if given to those who have the most to gain: preadolescent girls and women up to age 21. Authors of the study, in today's New England Journal of Medicine, measured the Gardasil vaccine's value by calculating the cost of giving one person an extra healthy year of life and balancing the...

By Elisabeth Rosenthal In two years, cervical cancer has gone from obscure killer confined mostly to poor nations to the West's disease of the moment. Tens of millions of girls and young women have been vaccinated against the disease in the United States and in Europe in the two years since two vaccines were given government approval in many countries and, often, recommended for universal use among females from 11 to 26. One of the vaccines, Gardasil, from Merck, is paid for by the...

Vical has announced a research collaboration with the Karolinska Institute, a European medical university, and the Swedish Institute for Infectious Disease Control, a governmental expert agency, to evaluate the company's Vaxfectin adjuvant with the Biojector 2000 needle-free injection system for a multivalent preventive DNA vaccine against HIV. The Karolinska Institute has completed a 38-subject Phase I trial testing a prime-boost HIV vaccine regimen using three doses of unadjuvanted DNA...

A group of doctors in Australia say a review of a cervical cancer vaccine is needed after three treated patients contracted pancreatitis. Surgery fellow Amitabha Das said he and several colleagues called for a major review of the Gardasil vaccine after three female patients injected with the quadrivalent medication were later diagnosed with pancreatitis, The Melbourne Sun-Herald reported in its Sunday edition. "We suggest that pancreatitis be considered in cases of abdominal pain following...

By Keith Lawrence, Messenger-Inquirer, Owensboro, Ky. Jul. 24--Owensboro's Kentucky BioProcessing LLC has signed a deal that could have a huge impact on the region's economy -- if a new human papillomavirus vaccine is successful. Louisville-based Advanced Cancer Therapeutics has signed a deal with the University of Louisville's James Graham Brown Cancer Center to license its technology for a second-generation HPV vaccine. And a second deal with Kentucky BioProcessing will allow ACT to...